% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Meyer:287071,
author = {M. Meyer$^*$ and C. Parpoulas$^*$ and T. Barthélémy$^*$
and J. P. Becker$^*$ and P. Charoentong$^*$ and Y. Lyu$^*$
and S. Börsig$^*$ and N. Bulbuc$^*$ and C. Tessmer$^*$ and
L. Weinacht$^*$ and D. Ibberson and P. Schmidt$^*$ and R.
Pipkorn$^*$ and S. B. Eichmüller$^*$ and P. Steinberger and
K. Lindner$^*$ and I. Poschke$^*$ and M. Platten$^*$ and S.
Fröhling$^*$ and A. B. Riemer$^*$ and J. C. Hassel and M.
P. Roberti$^*$ and D. Jäger$^*$ and I. Zörnig$^*$ and F.
Momburg$^*$},
title = {{M}edi{M}er: a versatile do-it-yourself peptide-receptive
{MHC} class {I} multimer platform for tumor
neoantigen-specific {T} cell detection.},
journal = {Frontiers in immunology},
volume = {14},
issn = {1664-3224},
address = {Lausanne},
publisher = {Frontiers Media},
reportid = {DKFZ-2024-00164},
pages = {1294565},
year = {2023},
note = {#EA:D121#EA:D120#LA:D120# / HI-TRON / Front Immunol. 2023;
14: 1294565.Published online 2024 Jan 4. doi:
10.3389/fimmu.2023.1294565 / in 2023 mitgezählt},
abstract = {Peptide-loaded MHC class I (pMHC-I) multimers have
revolutionized our capabilities to monitor
disease-associated T cell responses with high sensitivity
and specificity. To improve the discovery of T cell
receptors (TCR) targeting neoantigens of individual tumor
patients with recombinant MHC molecules, we developed a
peptide-loadable MHC class I platform termed MediMer.
MediMers are based on soluble disulfide-stabilized
β2-microglobulin/heavy chain ectodomain single-chain dimers
(dsSCD) that can be easily produced in large quantities in
eukaryotic cells and tailored to individual patients' HLA
allotypes with only little hands-on time. Upon transient
expression in CHO-S cells together with ER-targeted BirA
biotin ligase, biotinylated dsSCD are purified from the cell
supernatant and are ready to use. We show that CHO-produced
dsSCD are free of endogenous peptide ligands. Empty dsSCD
from more than 30 different HLA-A,B,C allotypes, that were
produced and validated so far, can be loaded with synthetic
peptides matching the known binding criteria of the
respective allotypes, and stored at low temperature without
loss of binding activity. We demonstrate the usability of
peptide-loaded dsSCD multimers for the detection of human
antigen-specific T cells with comparable sensitivities as
multimers generated with peptide-tethered β2m-HLA heavy
chain single-chain trimers (SCT) and wild-type peptide-MHC-I
complexes prior formed in small-scale refolding reactions.
Using allotype-specific, fluorophore-labeled competitor
peptides, we present a novel dsSCD-based peptide binding
assay capable of interrogating large libraries of in silico
predicted neoepitope peptides by flow cytometry in a
high-throughput and rapid format. We discovered rare T cell
populations with specificity for tumor neoepitopes and
epitopes from shared tumor-associated antigens in peripheral
blood of a melanoma patient including a so far unreported
HLA-C*08:02-restricted NY-ESO-1-specific CD8+ T cell
population. Two representative TCR of this T cell
population, which could be of potential value for a broader
spectrum of patients, were identified by dsSCD-guided
single-cell sequencing and were validated by cognate pMHC-I
multimer staining and functional responses to autologous
peptide-pulsed antigen presenting cells. By deploying the
technically accessible dsSCD MHC-I MediMer platform, we hope
to significantly improve success rates for the discovery of
personalized neoepitope-specific TCR in the future by being
able to also cover rare HLA allotypes.},
keywords = {T cell receptor discovery (Other) / T cells (Other) /
neoepitope screening (Other) / peptide-MHC class I multimer
(Other) / personalized medicine (Other) / tumor
immunotherapy (Other) / tumor neoantigen (Other)},
cin = {D121 / D120 / D410 / D210 / D170 / HD01 / B340},
ddc = {610},
cid = {I:(DE-He78)D121-20160331 / I:(DE-He78)D120-20160331 /
I:(DE-He78)D410-20160331 / I:(DE-He78)D210-20160331 /
I:(DE-He78)D170-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)B340-20160331},
pnm = {314 - Immunologie und Krebs (POF4-314)},
pid = {G:(DE-HGF)POF4-314},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38239352},
pmc = {pmc:PMC10794645},
doi = {10.3389/fimmu.2023.1294565},
url = {https://inrepo02.dkfz.de/record/287071},
}